Published in Lancet on June 13, 1998
SPRINT Trial Type Blood Pressure Measurements in Patients After Kidney Transplantation | NCT03094702
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Collaborative care for patients with depression and chronic illnesses. N Engl J Med (2010) 8.92
British Hypertension Society guidelines for hypertension management 1999: summary. BMJ (1999) 8.80
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ (2004) 7.92
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ (2001) 4.66
The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care (2013) 4.08
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 3.88
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (2009) 3.83
Diabetes in older adults: a consensus report. J Am Geriatr Soc (2012) 3.63
Diabetes in older adults. Diabetes Care (2012) 3.62
Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med (2006) 3.55
Projecting the future diabetes population size and related costs for the U.S. Diabetes Care (2009) 3.34
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc (2001) 3.06
A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus. J Am Med Inform Assoc (2005) 3.01
Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension (2008) 2.96
Features of primary care associated with variations in process and outcome of care of people with diabetes. Br J Gen Pract (2001) 2.95
Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract (2005) 2.83
Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing? Arch Intern Med (2012) 2.75
The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke (2011) 2.35
Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am J Hypertens (2008) 2.31
Risk of major gastrointestinal bleeding with aspirin. Lancet (1999) 2.24
Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev (2015) 2.19
Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract (2006) 2.10
Heart failure: epidemiology and prevention in India. Natl Med J India (2011) 2.09
The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers. Health Serv Res (2007) 2.09
Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med (2010) 2.06
2009 Canadian Hypertension Education Program recommendations: an annual update. Can Fam Physician (2009) 2.03
Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension (2010) 2.02
Can a chronic care model collaborative reduce heart disease risk in patients with diabetes? J Gen Intern Med (2007) 1.92
Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation (2013) 1.89
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ (2000) 1.87
Blood pressure and stroke risk among diabetic patients. J Clin Endocrinol Metab (2013) 1.79
Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation (2009) 1.77
Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol (2014) 1.71
Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes (2014) 1.71
Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia (2008) 1.70
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension (2011) 1.65
Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) (2011) 1.59
Diabetes care needs evidence based interventions to reduce risk of vascular disease. BMJ (2000) 1.57
Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. J Gen Intern Med (2010) 1.55
Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med (2007) 1.54
When there is too much to do: how practicing physicians prioritize among recommended interventions. J Gen Intern Med (2004) 1.53
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PLoS One (2016) 1.52
Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract (2008) 1.49
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int (2006) 1.47
Long-term effects of stress reduction on mortality in persons > or = 55 years of age with systemic hypertension. Am J Cardiol (2005) 1.46
Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol (2011) 1.45
Diabetic nephropathy. Diabetol Metab Syndr (2009) 1.43
Effective diabetes care: a need for realistic targets. BMJ (2002) 1.43
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ (2013) 1.43
Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol (2008) 1.43
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 1.43
Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk? Eur J Clin Pharmacol (2005) 1.42
Updated national and international hypertension guidelines: a review of current recommendations. Drugs (2014) 1.41
Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med (2005) 1.41
Modifications of coronary risk factors. Am J Cardiol (2006) 1.41
Carotid endarterectomy benefits patients with CKD and symptomatic high-grade stenosis. J Am Soc Nephrol (2009) 1.40
Ophthalmology and general medicine. Postgrad Med J (2000) 1.39
The economic costs of diabetes: is it time for a new treatment paradigm? Diabetes Care (2013) 1.38
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension (2012) 1.35
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care (2010) 1.31
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
After-hours colorectal surgery: a risk factor for anastomotic leakage. Int J Colorectal Dis (2009) 1.29
The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol (1999) 1.29
Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med (2011) 1.27
Coronary artery calcium in relation to initiation and continuation of cardiovascular preventive medications: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Qual Outcomes (2010) 1.27
Treating hypertension with guidelines in general practice. BMJ (2004) 1.26
Estimating cardiovascular risk for primary prevention: outstanding questions for primary care. BMJ (2000) 1.24
Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag (2010) 1.24
Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23
Diabetes outcomes in the Indian health system during the era of the Special Diabetes Program for Indians and the Government Performance and Results Act. Am J Public Health (2005) 1.22
Commentary--improving diabetes care by combating clinical inertia. Health Serv Res (2005) 1.21
Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care (2013) 1.21
Blood pressure j-curve: current concepts. Curr Hypertens Rep (2012) 1.18
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol (2010) 1.17
Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician (2011) 1.17
Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care (2013) 1.16
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J (2003) 17.80
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ (1989) 4.76
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet (1981) 4.75
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol (1995) 4.50
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med (1992) 3.87
Coronary heart-disease after treatment of hypertension. Lancet (1978) 3.78
Smoking and myocardial infarction. Lancet (1975) 3.42
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Multivariate analysis of risk factors for coronary heart disease. Circulation (1973) 3.04
Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol (1999) 2.98
Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ (2001) 2.74
Comparison of Escherichia coli from bacteriuric patients with those from feces of healthy schoolchildren. J Infect Dis (1977) 2.72
Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed) (1987) 2.67
Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens (1987) 2.59
Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens (1995) 2.58
Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press (1992) 2.49
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation (1998) 2.40
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J (1996) 2.31
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation (1996) 2.23
Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest (1996) 2.20
Registration of myocardial infarction in the city of Göteborg, Sweden. J Chronic Dis (1975) 2.20
Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet (1983) 2.18
Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J (1973) 2.17
Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study. Eur Heart J (1999) 2.16
Home blood pressure determination. Value in borderline ("labile") hypertension. JAMA (1974) 2.16
Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res (1999) 2.11
Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation (2001) 2.08
European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens (2010) 2.06
Blood-pressure control in the hypertensive population. Lancet (1997) 2.05
The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press (1993) 2.03
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens (2007) 2.01
Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med (1998) 2.01
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol (2001) 1.94
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation (1975) 1.92
Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J (1983) 1.90
A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol (1969) 1.89
Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA (1988) 1.87
The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J (1986) 1.85
Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J (1996) 1.83
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
A comparison between participants and non-participants in a primary preventive trial. J Chronic Dis (1976) 1.80
Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension (1987) 1.80
White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? J Hypertens (1996) 1.79
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med (1997) 1.79
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension. Eur J Clin Pharmacol (1983) 1.77
The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press (1997) 1.76
Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens (2002) 1.75
Psychosocial factors and venous thromboembolism: a long-term follow-up study of Swedish men. J Thromb Haemost (2007) 1.74
Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res (1983) 1.74
Seasonal variations in home and ambulatory blood pressure in the PAMELA population. Pressione Arteriose Monitorate E Loro Associazioni. J Hypertens (1998) 1.73
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Home blood pressure monitoring. Arch Intern Med (2000) 1.71
High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension (1997) 1.71
Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest (1983) 1.70
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press (1994) 1.70
Evaluation of the baroreceptor-heart rate reflex by 24-hour intra-arterial blood pressure monitoring in humans. Hypertension (1988) 1.69
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med (1996) 1.68
The reaction of salivary substances with bacteria. J Oral Pathol (1975) 1.66
Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Göteborg, Sweden. Am J Epidemiol (1992) 1.66
Stressful life events, social support, and mortality in men born in 1933. BMJ (1993) 1.66
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
Home self blood pressure measurement in general practice. The SMART study. Self-measurement for the Assessment of the Response to Trandolapril. Am J Hypertens (1996) 1.66
High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med (1999) 1.62
Coronary heart disease, cancer and mortality in male middle-aged light smokers. J Intern Med (1992) 1.62
Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med (2004) 1.62
Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation (2001) 1.62
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J (1999) 1.61
Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Perspect Biol Med (1998) 1.57
Heart rate and the cardiovascular risk. J Hypertens (1997) 1.57
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens (2011) 1.56
Peak expiratory flow and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Am J Epidemiol (1986) 1.55
Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study. BMJ (1996) 1.54
Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients. Br J Clin Pharmacol (1984) 1.53
Coronary heart disease and mortality in middle aged men from different occupational classes in Sweden. BMJ (1988) 1.53
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet (2001) 1.52
Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy. J Hum Hypertens (2003) 1.51
Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ (1990) 1.50
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl (2004) 1.50
The homogeneity of the faecal coliform flora of normal school-girls, characterized by serological and biochemical properties. Med Microbiol Immunol (1978) 1.49
Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens (2005) 1.49
Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models. J Intern Med (2008) 1.49